Chronic Low Back Pain — Evidence-Based Care

Why This Article Exists
Red Flags — When Back Pain Is an Emergency
Inflammatory Back Pain — The Ankylosing Spondylitis Red Flag
Imaging — Why Magnetic Resonance Imaging Often Makes Things Worse
Most Chronic Back Pain Is Nociplastic, Not Structural
The ACP 2017 Guideline in Plain English
Movement Therapies — McKenzie, Motor Control, Feldenkrais
Mind-Body Therapies — Cognitive Behavioral Therapy, Yoga, Mindfulness, ACT
Medications — What Actually Works
Injections — Epidural Steroid and SI Joint
Surgery — The SPORT Trial and Its Limits
Pain Reprocessing Therapy — The Boulder Study
The Biopsychosocial Model
How the Guidelines and Trials Add Up to a Care Plan
Key Research Papers
Connections
Featured Videos

Why This Article Exists

Low back pain is the single leading cause of years lived with disability worldwide. Roughly 80% of adults will have a significant episode in their lifetime, and about 20% of those episodes turn chronic — meaning pain persists longer than three months. If you have been in pain that long, you already know the drill: doctors order a magnetic resonance imaging (MRI), the magnetic resonance imaging shows "something," a procedure or surgery is offered, and either nothing changes or the pain returns in a different place six months later.

The scientific consensus has shifted dramatically in the past fifteen years, but medical practice has not caught up. The best evidence says most chronic low back pain is not caused by the structural findings on your magnetic resonance imaging, that imaging in the absence of red flags makes outcomes worse, that first-line care is movement and mind-body therapy, and that opioids and most surgeries help far less than patients are told. This article walks through what the American College of Physicians, the Lancet series on back pain, and the major randomized trials actually recommend — and what that means for the options open to a person in pain.

Red Flags — When Back Pain Is an Emergency

Before anything else: the minority of back pain cases where structure really is the problem and delay is dangerous. These are the signs that doctors and emergency departments treat as same-day reasons for assessment.

Cauda equina syndrome — new loss of bladder or bowel control, numbness in the saddle area (inner thighs, perineum, buttocks), progressive weakness in both legs, or loss of sexual function. This is a surgical emergency within 24–48 hours. Delay causes permanent paralysis.
Cancer red flags — known history of cancer, unexplained weight loss, pain that is worse at night and unrelieved by position change, pain lasting more than 4–6 weeks unresponsive to conservative care, age over 50 with new onset.
Spinal infection — fever, intravenous (IV) drug use, recent bacteremia, immunosuppression, recent spine procedure, or severe night pain. Epidural abscess and discitis are missed routinely and devastating when delayed.
Fracture — recent significant trauma, or minor trauma plus osteoporosis, chronic steroid use, or age over 70. Vertebral compression fractures are often missed on exam and require imaging.
Progressive neurologic deficit — worsening foot drop, worsening leg weakness, or expanding numbness that you can track week by week.
Inflammatory back pain pattern (see next section) — suggests ankylosing spondylitis or axial spondyloarthritis.

In the absence of these features, imaging does not help and often hurts. That is not a statement of medical laziness — it is a finding backed by decades of trials.

Inflammatory Back Pain — The Ankylosing Spondylitis Red Flag

The one inflammatory disease hiding inside the "chronic low back pain" population is axial spondyloarthritis, of which ankylosing spondylitis is the classic form. The average delay from symptom onset to ankylosing spondylitis (AS) diagnosis is still seven to ten years. Most of that delay comes from primary care physicians treating inflammatory back pain as ordinary mechanical back pain.

The pattern is unmistakable once you know it. The screening questions are:

Did the pain start before age 45?
Has it lasted more than three months?
Is morning stiffness longer than one hour, easing only after you move around?
Does the pain wake you in the second half of the night?
Do you feel it in the buttocks, sometimes alternating sides?
Does it improve with exercise and worsen with rest — the opposite of a mechanical disc or muscle problem?
Do nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen) work remarkably well?

When three or more of those apply, the standard workup is a magnetic resonance imaging of the sacroiliac joints (not the lumbar spine) and a human leukocyte antigen-B27 blood test, usually ordered by a rheumatologist. The lab cost is under $150, the magnetic resonance imaging is the definitive test, and catching axial spondyloarthritis early changes the trajectory of the disease. See human leukocyte antigen-B27 Explained for what that test means, and the arthritis overview for how the spondyloarthropathies fit with other inflammatory joint diseases.

Imaging — Why Magnetic Resonance Imaging Often Makes Things Worse

The single most important study for any chronic back pain patient to understand is Brinjikji et al. 2015 — a systematic review of 33 studies covering 3,110 people who had no back pain at all and received spinal MRIs anyway. The findings:

Disc degeneration on magnetic resonance imaging: 37% of asymptomatic 20-year-olds, rising to 96% of asymptomatic 80-year-olds.
Disc bulges: 30% at age 20, 84% at age 80.
Disc protrusions: 29% at age 20, 43% at age 80.
Annular fissures: 19% at age 20, 29% at age 80.

Translation: almost every finding a radiologist writes on your magnetic resonance imaging report — bulge, protrusion, degeneration, desiccation, facet arthropathy, foraminal narrowing — is present at similar rates in people without pain. Those findings are normal age-related changes, like gray hair and wrinkles, not pain generators.

What the studies also show is that getting a magnetic resonance imaging for non-specific back pain makes outcomes worse. Patients who get early imaging have more surgery, more injections, more opioid prescriptions, higher costs, more work absence, and similar or worse pain scores compared with matched patients who skip imaging. The mechanism is straightforward: the magnetic resonance imaging report plants the idea of a broken back, fear drives avoidance of movement, avoidance drives deconditioning, deconditioning drives more pain. The scan itself becomes a nocebo.

The ACP and every major guideline now say: no imaging for non-specific low back pain within the first six weeks, and no imaging after that unless red flags appear or a specific procedure hinges on the result. If you already have a magnetic resonance imaging report full of alarming-sounding findings, the appropriate reaction is relief, not dread. Given Brinjikji 2015, the open question for any such report is whether those findings explain the pain at all.

Most Chronic Back Pain Is Nociplastic, Not Structural

The International Association for the Study of Pain now recognizes three pain mechanisms: nociceptive (tissue damage — a cut, a sprain, arthritis), neuropathic (nerve damage — sciatica from a compressed root, diabetic neuropathy), and nociplastic (the nervous system itself has become the source). The third category covers fibromyalgia, chronic tension headache, irritable bowel syndrome, and — in most long-standing cases — chronic low back pain.

In nociplastic pain, the original injury has healed but the nervous system has learned to generate pain signals anyway. The brain's pain-processing networks become central sensitized: pain thresholds drop, non-painful touch starts feeling painful (allodynia), and the pain spreads beyond its original territory. This is not "psychological" pain — the pain is real, the brain activity is measurable on functional magnetic resonance imaging (fMRI), and telling a patient "it's in your head" is both wrong and counterproductive. But the treatment is fundamentally different from treating a torn disc. See Central Sensitization and Nociplastic Pain and Pain Types Explained for the mechanistic detail.

Clues that your back pain has gone nociplastic:

Pain has persisted long past the typical tissue-healing window (6–12 weeks).
Pain location shifts — one day the left side, next week the right, next month the neck.
Pain intensity correlates with stress, poor sleep, or emotional triggers more than with physical activity.
You also have fatigue, brain fog, irritable bowel syndrome (IBS), migraine, or other chronic pain syndromes.
Magnetic resonance imaging shows findings no worse than your asymptomatic friends' findings.
Light touch on the skin over the painful area feels unpleasant or burning.

For people with this pattern, the good news in the research is that nociplastic pain is often more reversible than structural pain, not less.

The ACP 2017 Guideline in Plain English

In 2017 the American College of Physicians published the most influential modern guideline on low back pain (Qaseem et al., Annals of Internal Medicine). Its central recommendation inverted fifty years of practice: for chronic low back pain, non-drug therapy comes first, drugs come second, and opioids come last if at all.

First-line therapies (a strong recommendation, based on moderate-quality evidence for exercise, multidisciplinary rehabilitation, acupuncture and mindfulness-based stress reduction, and low-quality evidence for the rest):

Exercise — any kind you will actually do. Aerobic, strengthening, water-based, McKenzie extension, motor control. The specific type matters less than consistency.
Multidisciplinary rehabilitation — a program that combines PT with cognitive behavioral therapy (CBT) and graded activity.
Acupuncture — modest but real effect sizes in meta-analyses.
Mindfulness-based stress reduction (MBSR) — equivalent to cognitive behavioral therapy in head-to-head trials.
Tai chi.
Yoga — particularly Iyengar and Viniyoga styles studied in trials.
Motor control exercise.
Progressive relaxation.
Electromyography biofeedback.
Low-level laser therapy.
Operant therapy.
Cognitive behavioral therapy (CBT).
Spinal manipulation.

Second-line (if first-line insufficient): nonsteroidal anti-inflammatory drugs (NSAIDs) (ibuprofen, naproxen) as the preferred drug. Duloxetine or tramadol as a next step. Acetaminophen is explicitly demoted — the Paracetamol for Low-Back Pain Study (PACE trial, 2014), in people with new (acute) low back pain, found that regular or as-needed paracetamol did not shorten recovery time compared with placebo (median 17 versus 16 days).

Last resort: opioids, and only "after a discussion of known risks and realistic benefits" and only when other options have failed. The implicit message — explicit in newer 2022 U.S. Centers for Disease Control and Prevention (CDC) guidance — is that opioids for chronic non-cancer back pain almost never make sense as long-term therapy. See Opioids for Chronic Non-Cancer Pain.

Movement Therapies — McKenzie, Motor Control, Feldenkrais

"Exercise" is the most under-prescribed, over-hedged therapy in all of medicine. Every meta-analysis says it works. The trick is finding the style you will stick with.

McKenzie Method (Mechanical Diagnosis and Therapy). A systematic approach built around repeated end-range movements — most famously prone press-ups (lying face-down, propping up on the elbows or hands). The therapist identifies the single movement that "centralizes" your pain (pulls it from the leg back toward the spine) and assigns it as homework, sometimes hundreds of reps a day. Works best for patients with a clear directional preference. McKenzie-trained therapists carry Cred-MDT or Dip-MDT credentials.

Motor control exercise. Teaches the deep stabilizing muscles (transverse abdominis, multifidus) to fire automatically before and during movement. Modest advantage over general exercise in trials, but the real benefit is reconnecting you with muscles you have stopped trusting. A well-trained PT can teach the core activation patterns in four to six sessions.

Feldenkrais and Alexander Technique. Movement-awareness disciplines that retrain habitual posture and tension patterns. Randomized trial evidence is modest but encouraging, particularly for people whose pain is tied to chronic guarding.

Yoga and tai chi. Multiple randomized controlled trials (RCTs) show durable benefit for chronic low back pain, comparable to conventional PT. Trials mostly used Iyengar and Viniyoga styles; teachers describe beginner Iyengar or gentle hatha as gentle starting points, and power yoga as able to re-injure a sensitized back.

Walking. The most underrated therapy. Practitioners describe thirty to forty-five minutes daily, outdoors if possible, builds aerobic fitness, releases endogenous opioids and endocannabinoids, and directly improves disc nutrition (the discs depend on movement for their fluid exchange).

The central principle in this research: movement is the medicine. Bed rest longer than 48 hours actively delays recovery. When activity is avoided out of fear of "making it worse," that fear itself becomes part of the pain problem. See Sleep, Exercise, and Lifestyle for Chronic Pain.

Mind-Body Therapies — Cognitive Behavioral Therapy, Yoga, Mindfulness, ACT

For chronic pain the brain is not a metaphor — it is the final common pathway where all pain is constructed. Interventions that change how the brain processes pain signals change the pain itself.

Cognitive behavioral therapy (CBT) for chronic pain. Eight to twelve sessions that target catastrophic thinking ("this pain will destroy my life"), fear-avoidance, activity pacing, and sleep. Effect sizes are modest but durable, and comparable to most pharmacotherapy. Many insurance plans now cover it.

Mindfulness-Based Stress Reduction (MBSR). The Cherkin 2016 JAMA trial compared MBSR, CBT, and usual care for chronic low back pain. MBSR and cognitive behavioral therapy both beat usual care, and the two were equivalent to each other. Eight weekly group sessions plus home practice. Community MBSR programs are often cheaper than therapy.

Acceptance and Commitment Therapy (ACT). Rather than trying to reduce pain, ACT teaches you to act according to your values even when pain is present — a subtle shift that paradoxically often reduces suffering and pain intensity.

Pain Neuroscience Education (PNE). Learning how pain actually works — that pain is produced by the brain, not the tissues; that your magnetic resonance imaging findings are not the cause; that hurt does not equal harm — reliably reduces pain and fear in trials. Self-help books on pain neuroscience education are widely available. See Pain Reprocessing Therapy and PNE.

Cognitive functional therapy (CFT). The RESTORE trial (Kent et al., Lancet 2023) tested this physiotherapy approach, which combines movement retraining with changing unhelpful beliefs and fears about pain, in 492 Australians with chronic, disabling low back pain. Up to seven sessions over 12 weeks plus a booster at 26 weeks cut activity limitation by 4.6 points on the 24-point Roland Morris disability scale compared with usual care at 13 weeks; the effect was similar at 52 weeks, and the therapy cost society considerably less than usual care.

Medications — What Actually Works

A blunt summary of the drug landscape for chronic non-specific back pain:

Nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, diclofenac, meloxicam): small benefit: a 2016 Cochrane review of 6 placebo-controlled trials (1,354 people) with chronic low back pain found pain about 3 points lower on a 100-point scale than with placebo, and disability less than 1 point lower on a 24-point scale (low-quality evidence). First-line drug. Long-term use carries stomach, kidney, and cardiovascular risk.
Acetaminophen: in the PACE trial it did not speed recovery from new (acute) low back pain compared with placebo; that trial did not test chronic pain.
Muscle relaxants (cyclobenzaprine, methocarbamol, tizanidine): mild short-term benefit, sedating. Used for acute flares rather than chronic daily use.
Duloxetine: serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant with U.S. Food and Drug Administration (FDA) approval for chronic musculoskeletal pain. Works independent of mood effect. Modest but real benefit.
Gabapentin and pregabalin: disappointing in back pain trials. Useful for clear-cut radicular (sciatic) pain, weak for axial back pain, and now under scrutiny for overprescription and misuse. See Non-Opioid Medications.
Tricyclics (amitriptyline, nortriptyline): low-dose, mostly for sleep and for pain with a neuropathic flavor.
Tramadol: weak opioid plus serotonin-norepinephrine reuptake inhibitor action. Effective but still an opioid, with dependence potential often underestimated.
Low-dose naltrexone: off-label, cheap, well-tolerated, with emerging evidence in nociplastic pain conditions.
Opioids: never demonstrated long-term benefit for chronic back pain in any randomized controlled trial (RCT). The SPACE trial (Krebs 2018, JAMA) randomized 240 patients with moderate to severe chronic back pain or hip or knee osteoarthritis pain to opioid versus non-opioid medicines for one year — pain-related function was no different between the groups, pain was somewhat lower (3.5 versus 4.0 on a 10-point scale) and medication side effects fewer with the non-opioid medicines. The authors concluded the results do not support starting opioid therapy for these pains, and the ACP 2017 guideline places opioids last. See Opioids for Chronic Non-Cancer Pain.
Opioids for new back or neck pain: the OPAL trial (Jones et al., Lancet 2023) gave 347 people with back or neck pain of 12 weeks or less an opioid (oxycodone-naloxone) or an identical placebo for up to 6 weeks. Pain at 6 weeks was no better with the opioid (2.78 versus 2.25 on a 10-point scale), and constipation was more common (7.5% versus 3.5%).

Injections — Epidural Steroid and SI Joint

Epidural steroid injections (ESI) are among the most commonly performed procedures in pain medicine. The evidence is narrower than the practice suggests:

For acute radiculopathy (sciatica from a disc) with leg pain worse than back pain, ESI produces a modest short-term benefit (2–6 weeks) on leg pain. Effect fades by 3 months.
For axial (non-radicular) back pain, ESI does not reliably help.
ESI does not change the rate of eventual surgery in most trials, though it may delay it.
Risks are small but not zero: transient glucose elevation, rare dural puncture, very rare spinal cord injury (especially with transforaminal cervical injections).

Sacroiliac (SI) joint injections are both diagnostic and therapeutic. If a fluoroscopy-guided intra-articular injection of local anesthetic produces >75% pain relief for the duration of the anesthetic, the SI joint is the likely pain generator — a small but real subgroup. Therapeutic benefit from steroid varies; radiofrequency ablation of the sacral lateral branches offers longer relief in responders.

Medial branch blocks and facet radiofrequency ablation help a subset of patients with facet-mediated pain. Success rates reported in the literature are wide (30–80%) and depend heavily on strict patient selection with dual diagnostic blocks.

The honest framing: injections are a bridge, not a destination. They can buy weeks or months of reduced pain in which the movement and mind-body work that actually rewires the system can be done. See Interventional Pain for the full menu.

Surgery — The SPORT Trial and Its Limits

The Spine Patient Outcomes Research Trial (SPORT), published in a series of JAMA and NEJM papers starting in 2006, is the most rigorous comparison of spinal surgery versus non-operative care ever performed. It covered three conditions: lumbar disc herniation, spinal stenosis, and degenerative spondylolisthesis. The headline findings:

For disc herniation with sciatica (the 2006 randomized trial of 501 patients): both groups improved substantially over 2 years. Crossover was heavy — only 50% of those assigned to surgery had it within 3 months, while 30% of those assigned to non-operative care had surgery in the same period — and in the intention-to-treat analysis the differences favoured surgery at every time point but were small and not statistically significant for the main outcomes. Because so many patients crossed over, the authors judged that the trial could not show whether one treatment was better.
For spinal stenosis: decompression surgery had a modest but durable advantage at 2–4 years for leg pain and walking capacity.
For degenerative spondylolisthesis with stenosis: surgery had the largest advantage over non-operative care, but still roughly a third of non-operative patients did well.
For non-specific axial back pain with degenerative changes but no clear nerve compression: fusion surgery has not shown durable benefit over intensive rehabilitation in any rigorous trial. This is the single most common reason chronic back pain patients are offered surgery, and it is the reason with the worst evidence.

What SPORT and the follow-on literature show is that spinal surgery is highly useful in a narrow set of indications (progressive neurologic deficit, severe refractory sciatica with matching imaging, clear stenosis with neurogenic claudication, cauda equina, fracture, tumor, infection) and unreliable to actively harmful outside those indications. "Failed back surgery syndrome" is common enough to have its own ICD code. Fusion for axial back pain with magnetic resonance imaging findings but no red flags and no clear neural compression is the indication with the weakest trial evidence, as the list above shows.

Pain Reprocessing Therapy — The Boulder Study

The most important recent addition to the evidence base is Pain Reprocessing Therapy (PRT), tested in the Boulder Back Pain Study (Ashar et al., JAMA Psychiatry, 2022). The trial randomized 151 adults with chronic back pain (average 10 years of pain, average pain 4/10) to one of three arms: four weeks of PRT (one telehealth visit with a doctor plus 8 psychological treatment sessions), an open-label placebo injection of salt water in the back (patients knew it was a placebo), or usual care.

Results:

66% of PRT patients were pain-free or nearly pain-free at the end of treatment, compared with 20% of placebo and 10% of usual care.
Average pain fell from about 4.1 out of 10 at the start to 1.18 with PRT, against 2.84 with the open-label placebo and 3.13 with usual care.
Benefits were largely maintained at one-year follow-up: average pain 1.51 with PRT, 2.79 with placebo and 3.00 with usual care.
Functional magnetic resonance imaging showed measurable changes in brain regions involved in pain processing.

PRT is built on the premise that chronic back pain is often a learned neural circuit — a false alarm the brain has gotten very good at producing. The therapy combines pain neuroscience education, somatic tracking (feeling the pain with curiosity rather than fear), and cognitive work on the fear-pain loop. It is not magic, it is not appropriate when red flags are present, and it does not work for everyone — but for the substantial fraction of chronic back pain patients whose pain is nociplastic, it is the most effective intervention yet tested. What is not known: the volunteers came from a university community sample and had low-to-moderate pain (average disability 23 out of 100), so the results may not carry over to more severe or disabling pain. See Pain Reprocessing Therapy and PNE.

The Biopsychosocial Model

The old model of back pain was purely biomedical: something is broken in the spine, fix the thing, pain goes away. The old model fails for most chronic back pain. The biopsychosocial model, proposed by George Engel in 1977 and refined by pain researchers since, holds that chronic pain emerges from the interaction of three layers:

Biological — tissue factors, inflammation, nerve sensitization, sleep, hormones.
Psychological — catastrophizing, fear-avoidance, depression, anxiety, past trauma, attention and meaning.
Social — work demands, relationships, disability incentives, cultural beliefs about pain, healthcare interactions.

Every one of those layers contributes measurably to chronic pain outcomes. Focusing only on the biological layer is why medicine has spent forty years ordering MRIs, doing injections, and watching chronic back pain get worse as a public health problem, not better. A proper care plan addresses all three layers simultaneously.

How the Guidelines and Trials Add Up to a Care Plan

For back pain lasting longer than three months with no red flags, the guidelines and trials above point to this sequence:

Red-flag screening first. A primary care check for the red flags above and the inflammatory-back-pain questions for axial spondyloarthritis, with no imaging unless that screen finds something.
Physical therapy built on the modern model — motor control, McKenzie, or pain neuroscience education — rather than ultrasound and three stretches to take home.
Daily walking, built up a few minutes a week from wherever a person starts.
One mind-body therapy kept up for about eight weeks: an MBSR class, cognitive behavioral therapy for chronic pain, yoga, or a PRT-oriented therapist.
Pain-neuroscience education, which trials find reduces pain and fear; self-help books on pain neuroscience education are an inexpensive way to get it.
Sleep. Poor sleep amplifies pain the next day, measurably. See Sleep, Exercise, and Lifestyle for Chronic Pain.
Nonsteroidal anti-inflammatory drugs as an adjunct, not a strategy, used for flares. Duloxetine is the guideline’s second-line drug option.
Injections have their evidence in clear radiculopathy and in the diagnostic SI-joint question.
Fusion offered for axial pain without red flags is the operation with the weakest trial support (see the surgery section).
Reassessment at 12 weeks, with the same pain and function measures each time.

Key Research Papers

Brinjikji W, et al. Systematic literature review of imaging features of spinal degeneration in asymptomatic populations. AJNR. 2015. — doi:10.3174/ajnr.A4173
Qaseem A, et al. Noninvasive treatments for acute, subacute, and chronic low back pain: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017. — doi:10.7326/M16-2367
Ashar YK, et al. Effect of pain reprocessing therapy vs placebo and usual care for patients with chronic back pain: a randomized clinical trial (Boulder Back Pain Study). JAMA Psychiatry. 2022. PubMed PMID: 34586357
Krebs EE, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: The SPACE randomized clinical trial. JAMA. 2018. — doi:10.1001/jama.2018.0899
Cherkin DC, et al. Effect of mindfulness-based stress reduction vs cognitive behavioral therapy or usual care on back pain and functional limitations in adults with chronic low back pain. JAMA. 2016. — doi:10.1001/jama.2016.2323
Foster NE, et al. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet. 2018;391(10137):2368-2383. — doi:10.1016/S0140-6736(18)30489-6
Weinstein JN, et al. Surgical vs nonoperative treatment for lumbar disk herniation: the Spine Patient Outcomes Research Trial (SPORT): a randomized trial. JAMA. 2006;296(20):2441-2450. — doi:10.1001/jama.296.20.2441
Williams CM, et al. Efficacy of paracetamol for acute low-back pain: a double-blind, randomised controlled trial (PACE). Lancet. 2014. — doi:10.1016/S0140-6736(14)60805-9
Enthoven WT, et al. Non-steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database Syst Rev. 2016;2:CD012087. — doi:10.1002/14651858.CD012087
Kent P, et al. Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): a randomised, controlled, three-arm, parallel group, phase 3, clinical trial. Lancet. 2023;401(10391):1866-1877. — doi:10.1016/S0140-6736(23)00441-5
Jones CMP, et al. Opioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial. Lancet. 2023;402(10398):304-312. — doi:10.1016/S0140-6736(23)00404-X

PubMed Topic Searches

For further reading, the following PubMed topic searches return current peer-reviewed work on chronic low back pain assessment and management:

Back to Table of Contents